NeurAxis Announces Results Of Comparative Study Of IB-Stim And Standard Medical Therapy In Adolescents With Functional Abdominal Pain Disorders
Portfolio Pulse from Benzinga Newsdesk
NeurAxis (NYSE:NRXS) announced the results of a comparative study of adolescent patients with functional abdominal pain disorders (FAPD) treated with IB-Stim™ therapy or standard of care medications. The study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD. The study showed that IB-Stim™ therapy showed improvements in abdominal pain and functional disability compared to baseline, while amitriptyline showed improvements in abdominal pain. IB-Stim™ was more effective than cyproheptadine in improving abdominal pain and did not differ from amitriptyline.
September 26, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeurAxis's IB-Stim™ therapy shows potential as a non-pharmacologic alternative for treating functional abdominal pain disorders in adolescents. This could potentially increase the demand for the product and positively impact the company's stock.
The positive results from the comparative study of NeurAxis's IB-Stim™ therapy could potentially increase the demand for the product, especially considering the lack of effective alternatives for treating functional abdominal pain disorders in adolescents. This could lead to increased revenues for the company, which would likely have a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100